OlympiAD: PARP Inhibitor Olaparib Monotherapy in HER2-Negative, < i > BRCA < /i > -Mutated MBC

Slideset - Study data showed significantly prolonged PFS and a lower rate of high-grade adverse events with olaparib monotherapy vs CT.
Source: Clinical Care Options Breast Cancer - Category: Cancer & Oncology Source Type: research